Cargando…

Perspective of SGLT2i in the Treatment of Abdominal Aortic Aneurysms

The incidence of abdominal aortic aneurysm (AAA) in the elderly is increasing year by year with high mortality. Current treatment is mainly through surgery or endovascular intervention, which is not sufficient to reduce future risk. Therefore, we still need to find an effective conservative measure...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Zhongtiao, Deng, Hongping, Xiong, Sizheng, Gao, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Journal of Cardiovascular Pharmacology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079298/
https://www.ncbi.nlm.nih.gov/pubmed/36630701
http://dx.doi.org/10.1097/FJC.0000000000001395
_version_ 1785020699071479808
author Jin, Zhongtiao
Deng, Hongping
Xiong, Sizheng
Gao, Ling
author_facet Jin, Zhongtiao
Deng, Hongping
Xiong, Sizheng
Gao, Ling
author_sort Jin, Zhongtiao
collection PubMed
description The incidence of abdominal aortic aneurysm (AAA) in the elderly is increasing year by year with high mortality. Current treatment is mainly through surgery or endovascular intervention, which is not sufficient to reduce future risk. Therefore, we still need to find an effective conservative measure as an adjunct therapy or early intervention to prevent AAA progression. Traditional therapeutic agents, such as β-receptor blockers, calcium channel blockers, and statins, have been shown to have limited effects on the growth of AAA. Recently, sodium–glucose cotransport proteins inhibitors (SGLT2is), a new class hypoglycemic drug, have shown outstanding beneficiary effects on cardiovascular diseases by plasma volume reduction, vascular tone regulation, and various unidentified mechanisms. It has been demonstrated that SGLT2i is abundantly expressed in the aorta, and some studies also showed promising results of SGLT2i in treating animal AAA models. This article aims to summarize the recent progress of AAA studies and look forward to the application of SGLT2i in AAA treatment for early intervention or adjunct therapy after surgical repair or stent graft.
format Online
Article
Text
id pubmed-10079298
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Journal of Cardiovascular Pharmacology
record_format MEDLINE/PubMed
spelling pubmed-100792982023-04-07 Perspective of SGLT2i in the Treatment of Abdominal Aortic Aneurysms Jin, Zhongtiao Deng, Hongping Xiong, Sizheng Gao, Ling J Cardiovasc Pharmacol Review Article The incidence of abdominal aortic aneurysm (AAA) in the elderly is increasing year by year with high mortality. Current treatment is mainly through surgery or endovascular intervention, which is not sufficient to reduce future risk. Therefore, we still need to find an effective conservative measure as an adjunct therapy or early intervention to prevent AAA progression. Traditional therapeutic agents, such as β-receptor blockers, calcium channel blockers, and statins, have been shown to have limited effects on the growth of AAA. Recently, sodium–glucose cotransport proteins inhibitors (SGLT2is), a new class hypoglycemic drug, have shown outstanding beneficiary effects on cardiovascular diseases by plasma volume reduction, vascular tone regulation, and various unidentified mechanisms. It has been demonstrated that SGLT2i is abundantly expressed in the aorta, and some studies also showed promising results of SGLT2i in treating animal AAA models. This article aims to summarize the recent progress of AAA studies and look forward to the application of SGLT2i in AAA treatment for early intervention or adjunct therapy after surgical repair or stent graft. Journal of Cardiovascular Pharmacology 2023-01-11 /pmc/articles/PMC10079298/ /pubmed/36630701 http://dx.doi.org/10.1097/FJC.0000000000001395 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Review Article
Jin, Zhongtiao
Deng, Hongping
Xiong, Sizheng
Gao, Ling
Perspective of SGLT2i in the Treatment of Abdominal Aortic Aneurysms
title Perspective of SGLT2i in the Treatment of Abdominal Aortic Aneurysms
title_full Perspective of SGLT2i in the Treatment of Abdominal Aortic Aneurysms
title_fullStr Perspective of SGLT2i in the Treatment of Abdominal Aortic Aneurysms
title_full_unstemmed Perspective of SGLT2i in the Treatment of Abdominal Aortic Aneurysms
title_short Perspective of SGLT2i in the Treatment of Abdominal Aortic Aneurysms
title_sort perspective of sglt2i in the treatment of abdominal aortic aneurysms
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079298/
https://www.ncbi.nlm.nih.gov/pubmed/36630701
http://dx.doi.org/10.1097/FJC.0000000000001395
work_keys_str_mv AT jinzhongtiao perspectiveofsglt2iinthetreatmentofabdominalaorticaneurysms
AT denghongping perspectiveofsglt2iinthetreatmentofabdominalaorticaneurysms
AT xiongsizheng perspectiveofsglt2iinthetreatmentofabdominalaorticaneurysms
AT gaoling perspectiveofsglt2iinthetreatmentofabdominalaorticaneurysms